Rallybio Corp SEC filings RLYB
Rallybio Corp has 308 filings in SEC EDGAR's recent list, going back to May 7, 2018. Its latest annual report, Form 10-K, was filed on Mar 16, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Oct 27, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (officer or director change, shareholder vote results, other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEF 14A | Proxy statement | Jan 2, 2026 | Jan 26, 2026 |
| PRE 14A | Preliminary proxy statement | Dec 23, 2025 | Jan 26, 2026 |
| DEF 14A | Proxy statement | Apr 7, 2025 | Dec 31, 2024 |
| DEF 14A | Proxy statement | Apr 11, 2024 | Dec 31, 2023 |
| DEF 14A | Proxy statement | Apr 10, 2023 | May 17, 2023 |
| DEF 14A | Proxy statement | Apr 25, 2022 | May 24, 2022 |
Showing 6 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- RLYB (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New Haven, CT
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1739410
- Former names
- Rallybio Holdings, LLC (until Jun 7, 2021)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.